DMT210 Topical Gel in the Treatment of Acne Rosacea

Completed · Phase 2

Conditions studied: Acne Rosacea

In brief

The study evaluates the safety, tolerability, and efficacy of DMT210 Gel, 5% when applied twice daily for 12 weeks in adult patients with moderate to severe acne rosacea. Half of participants will receive DMT210 Gel while the other half will receive vehicle control.

Key facts

Study ID

NCT03003104

Run by

Dermata Therapeutics

People needed

107

Starts

2017-01-01

Expected to finish

2017-08-30

Last updated by the study team

2018-04-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient is male or non-pregnant female at least 18 years of age.
• Clinical diagnosis of moderate to severe facial rosacea as determined by Investigator's Global Assessment (IGA) at Randomization
• Patient has at least ten inflammatory lesions of rosacea on the face at Randomization
• Patient is willing to apply the Investigational Product as directed
• Patient is willing and able to comply with the protocol

You may not qualify if…

• Patient is pregnant or planning to become pregnant
• Patient is taking a topical therapy which may affect the patient's rosacea

Where it is running

• Dermata Investigational Site — San Diego, California, United States
• Dermata Investigational Site — Miami, Florida, United States
• Dermata Investigational Site — Fridley, Minnesota, United States
• Dermata Investigational Site — Omaha, Nebraska, United States
• Dermata Investigational Site — High Point, North Carolina, United States
• Dermata Investigational Site — Broomall, Pennsylvania, United States
• Dermata Investigational Site — Nashville, Tennessee, United States
• Dermata Investigational Site — Austin, Texas, United States
• Dermata Investigational Site — Norfolk, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.